Influence of Dystrophin Isoform Deficiency on Motor Development in Duchenne Muscular Dystrophy.
Chesshyre M. et al, (2025), Ann Clin Transl Neurol
Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.
Oskoui M. et al, (2025), Neurology, 104
Patient and caregiver spinal muscular atrophy treatment attribute preferences in Latin America.
Saenz V. et al, (2025), J Neuromuscul Dis
A systematic review on motor outcome measures in congenital myopathy.
Woods M. et al, (2025), Neuromuscul Disord
A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States.
Duong T. et al, (2025), Orphanet J Rare Dis, 20
Data-driven consideration of genetic disorders for global genomic newborn screening programs.
Minten T. et al, (2025), Genet Med, 27
Gene therapy approval for Duchenne muscular dystrophy: a European perspective.
Jolly H. et al, (2025), Lancet, 405, 1572 - 1573
Dystrophin isoform deficiency and upper-limb and respiratory function in Duchenne muscular dystrophy.
Chesshyre M. et al, (2025), Dev Med Child Neurol
X-linked myotubular myopathy: an untreated treatable disease.
Martin C. and Servais L., (2025), Expert Opin Biol Ther, 1 - 16
Newborn screening and rapid genomic diagnosis of neuromuscular diseases.
Dangouloff T. et al, (2025), J Neuromuscul Dis, 12, 157 - 172
Spinal muscular atrophy in the UK: the human toll of slow decisions.
Servais L. et al, (2025), Lancet, 405, 619 - 620
Biological biomarkers in muscle diseases relevant for follow-up and evaluation of treatment.
Stemmerik MG. et al, (2025), Brain, 148, 363 - 375
Wearable sensors in paediatric neurology.
González Barral C. and Servais L., (2025), Dev Med Child Neurol
Population-based, first-tier genomic newborn screening in the maternity ward.
Boemer F. et al, (2025), Nat Med
Pushing the boundaries: future directions in the management of spinal muscular atrophy.
Moultrie F. et al, (2025), Trends Mol Med
LAP1 Interactome Profiling Provides New Insights into LAP1's Physiological Functions.
Pereira CD. et al, (2024), Int J Mol Sci, 25
Treatment strategies for patients with spinal muscular atrophy.
De Waele L. and Servais L., (2024), Expert Rev Neurother, 1 - 3
Gene therapy for spinal muscular atrophy: timing is key.
Servais L., (2024), Lancet Reg Health Eur, 47